Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - travoprostas/timololis - akių lašai (tirpalas) - 40 µg/5 mg/ml - timolol, combinations

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - mometazono furoatas - nosies purškalas (suspensija) - 50 µg/dozėje - mometasone

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

ratiopharm gmbh - latanoprostas/timololis - akių lašai (tirpalas) - 50 µg/5 mg/ml - timolol, combinations

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - mometazono furoatas - nosies purškalas (suspensija) - 50 µg/dozėje - mometasone

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch + lomb ireland limited - travoprostas/timololis - akių lašai (tirpalas) - 40 µg/5 mg/ml - timolol, combinations

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

mylan pharmaceuticals limited - travoprostas/timololis - akių lašai (tirpalas) - 40 µg/5 mg/ml - timolol, combinations

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

n.v. organon - mometazono furoatas - nosies purškalas (suspensija) - 50 µg/dozėje - mometasone

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

medochemie ltd. - palonosetronas - injekcinis tirpalas - 250 µg - palonosetron

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

septinta s.p.r.l. - formoterolio fumaratas - įkvepiamieji milteliai (kietosios kapsulės) - 12 µg - formoterol

Uni Eropa - Lituavi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.